Search Results

You are looking at 1 - 1 of 1 items for :

  • Author: Alessandra Gambineri x
  • Metabolic Syndrome and Diabetes x
Clear All Modify Search
Sarantis Livadas Endocrine Unit, Athens Medical Centre, Athens, Greece

Search for other papers by Sarantis Livadas in
Google Scholar
PubMed
Close
,
Christina Bothou Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital of Zurich, Zurich, Switzerland

Search for other papers by Christina Bothou in
Google Scholar
PubMed
Close
,
Justyna Kuliczkowska-Płaksej Department of Endocrinology, Diabetology and Isotope Therapy, University of Medicine, Wrocław, Poland

Search for other papers by Justyna Kuliczkowska-Płaksej in
Google Scholar
PubMed
Close
,
Ralitsa Robeva Ushate ‘acad. IV. Penchev’, Department of Endocrinology, Faculty of Medicine, Medical University-Sofia, Sofia, Bulgaria

Search for other papers by Ralitsa Robeva in
Google Scholar
PubMed
Close
,
Andromahi Vryonidou Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, Greece

Search for other papers by Andromahi Vryonidou in
Google Scholar
PubMed
Close
,
Jelica Bjekic Macut Department of Endocrinology, UMC Bežanijska Kosa, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Search for other papers by Jelica Bjekic Macut in
Google Scholar
PubMed
Close
,
Ioannis Androulakis Endocrine Unit, Athens Medical Centre, Athens, Greece

Search for other papers by Ioannis Androulakis in
Google Scholar
PubMed
Close
,
Milica Opalic Clinic of Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Search for other papers by Milica Opalic in
Google Scholar
PubMed
Close
,
Zadalla Mouslech 1st Medical Propedeutic, Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Search for other papers by Zadalla Mouslech in
Google Scholar
PubMed
Close
,
Andrej Milewicz Department of Endocrinology, Diabetology and Isotope Therapy, University of Medicine, Wrocław, Poland

Search for other papers by Andrej Milewicz in
Google Scholar
PubMed
Close
,
Alessandra Gambineri Department of Medical and Surgical Science-DIMEC Endocrinology Unit, University of Bologna – S. Orsola-Mapighi Hospital, Italy

Search for other papers by Alessandra Gambineri in
Google Scholar
PubMed
Close
,
Dimitrios Panidis Gynaecological Endocrinology Infirmary of the Second Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece

Search for other papers by Dimitrios Panidis in
Google Scholar
PubMed
Close
, and
Djuro Macut Clinic of Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Search for other papers by Djuro Macut in
Google Scholar
PubMed
Close

Background

Polycystic ovary syndrome (PCOS) is considered a risk factor for the development of type 2 diabetes mellitus (T2DM). However, which is the most appropriate way to evaluate dysglycemia in women with PCOS and who are at increased risk are as yet unclear.

Aim of the study

To determine the prevalence of T2DM, impaired glucose tolerance (IGT), and impaired fasting glucose (IFG) in PCOS women and potential factors to identify those at risk.

Subjects and methods

The oral glucose tolerance test (OGTT), biochemical/hormonal profile, and ovarian ultrasound data from 1614 Caucasian women with PCOS and 362 controls were analyzed in this cross-sectional multicenter study. The data were categorized according to age and BMI.

Results

Dysglycemia (T2DM, IGT, and IFG according to World Health Organization criteria) was more frequent in the PCOS group compared to controls: 2.2% vs 0.8%, P = 0.04; 9.5% vs 7.4%, P = 0.038; 14.2% vs 9.1%, P = 0.002, respectively. OGTT was essential for T2DM diagnosis, since in 88% of them basal glucose values were inconclusive for diagnosis. The presence of either T2DM or IFG was irrespective of age (P = 0.54) and BMI (P = 0.32), although the latter was associated with IGT (P = 0.021). There was no impact of age and BMI status on the prevalence of T2DM or IFG. Regression analysis revealed a role for age, BMI, fat deposition, androgens, and insulin resistance for dysglycemia. However, none of the factors prevailed as a useful marker employed in clinical practice.

Conclusions

One-third of our cohort of PCOS women with either T2DM or IGT displayed normal fasting glucose values but without confirming any specific predictor for dysglycemic condition. Hence, the evaluation of glycemic status using OGTT in all women with PCOS is strongly supported.

Open access